Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Rating of "Hold" from Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has been assigned a consensus rating of "Hold" from the six research firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $7.00.

A number of brokerages have recently issued reports on RXRX. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target on the stock. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th.

Recursion Pharmaceuticals Trading Up 5.8%

Shares of Recursion Pharmaceuticals stock traded up $0.32 during mid-day trading on Friday, hitting $5.84. 52,851,764 shares of the stock were exchanged, compared to its average volume of 17,143,209. Recursion Pharmaceuticals has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a 50-day simple moving average of $4.92 and a 200 day simple moving average of $6.01. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The company had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same period last year, the firm posted ($0.39) earnings per share. Recursion Pharmaceuticals's quarterly revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Ensign Peak Advisors Inc increased its stake in shares of Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after acquiring an additional 1,300 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after acquiring an additional 1,353 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after buying an additional 1,875 shares during the last quarter. Clear Creek Financial Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 9.8% in the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock worth $113,000 after purchasing an additional 1,907 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after purchasing an additional 2,026 shares during the period. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.